Cardiovascular Protection of Aspirin in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis
CONCLUSION: Aspirin did not prevent CV events, with a significantly increased risk of minor bleeding and renal events. Besides, aspirin use had no statistically significant reduction in the risk of all-cause mortality but had a statistically significant reduction in the risk of CV mortality.PMID:37259222 | DOI:10.2174/1570161121666230530154647
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Ting Chen Yunlei Deng Rong Gong Source Type: research
More News: Aspirin | Bleeding | Cardiology | Cardiovascular | Chronic Kidney Disease | Databases & Libraries | Drugs & Pharmacology | Heart | Heart Attack | Heart Failure | Science | Statistics | Stroke | Study | Urology & Nephrology